Event Type
Disclosure
Mandatory
Variant
8-K
. Entry Into a Material Definitive Agreement. Exclusive License and Collaboration Agreement On November 4, 2025, Vaxart, Inc. (“Vaxart” or the “Company”) entere
, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Thompson Hine, dated November 5, 2025. 23.1 Consent of Thompson Hine (i